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ABSTRACT  
Hypertension Canada provides annually-updated, evidence-based guidelines for the 
diagnosis, assessment, prevention, and treatment of hypertension in adults and children. This 
year, the adult and pediatric guidelines are combined in one document. The new 2018 
pregnancy-specific hypertension guidelines are published separately.  
For 2018, 5 new guidelines were introduced, and one existing guideline on the blood 
pressure thresholds and targets in the setting of thrombolysis for acute ischemic stroke was 
revised. The use of validated wrist devices for the estimation of blood pressure in individuals 
with large arm circumference is now included. Guidance is provided for the follow-up 
measurements of blood pressure, with the use of standardized methods and electronic 
(oscillometric) upper arm devices in individuals with hypertension, and either ambulatory blood 
pressure monitoring or home blood pressure monitoring in individuals with white coat effect. We 
specify that all individuals with hypertension should have an assessment of global cardiovascular 
risk to promote health behaviours that lower blood pressure.  Finally, an angiotensin receptor-
neprilysin inhibitor combination should be used in place of either an angiotensin-converting 
enzyme inhibitor or angiotensin receptor blocker in individuals with heart failure (with ejection 
fraction < 40%) who are symptomatic despite appropriate doses of guideline-directed heart 
failure therapies.  The specific evidence and rationale underlying each of these guidelines are 
discussed.  
 
 
KEY WORDS: hypertension, high blood pressure, guidelines, recommendations, adults, 
pediatrics, diagnostic algorithm, blood pressure measurement, ambulatory blood pressure 
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monitoring, home blood pressure monitoring, automated blood pressure, global cardiovascular 
risk, lipid profile, tobacco, smoking cessation, renovascular disease, renal artery stenosis, 
primary aldosteronism, pheochromocytoma, pharmacotherapy, lifestyle.  
 
SUMMARY FOR ONLINE TABLE OF CONTENTS 
For 2018, 5 new guidelines were introduced and one existing guideline was revised. The 
use of wrist devices for the estimation of blood pressure in individuals with large arm 
circumference is included. Guidance is provided for follow-up measurements of blood pressure 
(hypertension with/without white coat effect). All individuals with hypertension should have an 
assessment of global cardiovascular risk.  Finally, an angiotensin receptor-neprilysin inhibitor 
combination should be used in individuals with heart failure meeting specific criteria. 
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Introduction 
Hypertension is one of the most common chronic diseases affecting Canadians across 
their lifespan – from approximately 2% of children and adolescents,1 to 7% of pregnant women,2 
to 25% of the adult population.3 Hypertension has broad impacts on the health of Canadians 
given its association with obesity (from childhood to adulthood)3,4 as well chronic kidney 
disease, cardiovascular disease, and death.3,5,6  Management of hypertension in children and 
adults centres around behavioural changes as well as pharmacotherapy, and is highly informed 
by individual cardiovascular risk.  Hypertension Canada continues to recommend a risk-based 
approach for treatment thresholds and targets, placing a strong emphasis on cardiovascular risk 
assessment not only for the purpose of therapeutic decision-making but also to engage and 
educate patients in risk reduction strategies. This year, adult and pediatric guidelines have been 
consolidated into a single clinical practice guidelines document.  Hypertension Canada’s 2018 
pregnancy-specific hypertension guidelines are published separately.  
Hypertension Canada (formerly the Canadian Hypertension Education Program, CHEP) 
has been producing annually-updated, evidence-based guidelines for health care providers since 
1999. Updated guidelines (new, revised and existing) are presented herein, along with discussion 
of the supporting evidence for the new and revised guidelines. Evidence along with 
corresponding references pertaining to previously established guidelines are available in prior 
publications,7-36 and online (guidelines.hypertension.ca).  
The guidelines are intended to provide a framework for evidence-based care of 
hypertension and do not supplant clinical judgment. Practitioners are advised to consider patient 
preferences, values, and clinical circumstances when determining how to best apply these 
guidelines to individual patients.37  
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Methods 
Hypertension Canada’s Guidelines are developed annually through a highly structured 
and systematic process designed to minimize bias. Hypertension Canada’s guideline process has 
been externally reviewed and is in concordance with the Appraisal of Guidelines for Research 
and Evaluation II (AGREE II) Instrument for guideline development 
(guidelines.hypertension.ca/about/overview-process).38  The Hypertension Canada Guidelines 
Committee (HCGC) is comprised of a multidisciplinary panel of both content and 
methodological experts divided into 16 subgroups that represent distinct areas of hypertension 
(Supplemental Appendix S1 for list of members and S2 for conflicts of interest).   
Comprehensive literature searches to August 2017 for each subgroup were performed by 
a trained medical librarian based on key words and terms provided by the subgroups. (Details of 
search strategies and retrieved articles are available upon request.)  The literature was reviewed 
in a standardized manner and was graded using an evidence-based grading scheme 
(Supplemental Table S1) which considered the following:  study methodologic quality; impacts 
on a hierarchy of validated clinical outcomes (priority given to cardiovascular morbidity and 
mortality); and that potential benefits must outweigh potential harms.  This process ensures that 
all Hypertension Canada Guidelines are graded according to the best available evidence.  For 
pharmacotherapy guidelines, Hypertension Canada considers evidence evaluating specific agents 
to be generalizable to a “class effect” unless otherwise stated.   
The guidelines were then reviewed by the Central Review Committee, unbiased experts 
in clinical epidemiology, to ensure that guidelines accurately reflected the evidence and to verify 
grading.  The draft guidelines and supporting evidence were presented to the HCGC in Toronto, 
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on October 12, 2017.  Following the discussions, the guidelines were further revised and 
finalized for an electronic vote by all 81 members of the HCGC, with greater than 70% support 
required for approval of each new/revised guideline. 
 
Hypertension Canada’s 2018 Guidelines  
Diagnosis and Assessment of Hypertension in Adults 
 
I. Accurate measurement of blood pressure (BP) 
Background. BP is traditionally measured using an upper arm cuff, however, recent studies 
suggest that accurate measurement of BP can be challenging in patients with increased upper arm 
size, particularly in obese patients with a body mass index (BMI) greater than 35 kg/m2,39,40  In 
these patients, there is a concern of hidden undercuffing (i.e., the cuff bladder is too small or 
narrow for the arm size) leading to falsely elevated BP values.39 A 2016 systematic review and 
meta-analysis examined the diagnostic accuracy of BP measurements of the forearm wrist and 
fingertip compared with correctly fitting upper arm cuff in obese individuals.  Compared with 
upper arm cuffs, wrist measurements (with the wrist held at the level of the heart) had the highest 
diagnostic accuracy for hypertension with a sensitivity of 0.92 (0.64-0.99) and specificity of 0.92 
(0.85-0.87),40 though individual studies reported discordant results for the classification by BP 
category.39   
 
Given the limitations of the available studies to date, an appropriately sized upper arm 
cuff remains the standard for BP measurement.40  However, when upper arm measurements are 
not possible due to extreme size of the arm or pain, a wrist measurement (with the arm and wrist 
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held at the level of the heart) may be used.39,40  When possible, concordance of wrist and upper 
arm device measurements should be demonstrated prior to the use of wrist BP measurements.39,40  
Measurement of fingertip BP is not recommended.38 
 
Guidelines. 
1. Health care professionals who have been specifically trained to measure BP accurately 
should assess BP in all adult patients at all appropriate visits to determine cardiovascular 
risk and monitor antihypertensive treatment (Grade D). 
2. Use of standardized measurement techniques and validated equipment for all methods 
(automated office BP [AOBP], non-AOBP, home BP monitoring, and ambulatory BP 
monitoring) is recommended (Grade D; see Supplemental Table S2; section III. Home BP 
Measurement; section IV. Ambulatory BP Measurement). Measurement using electronic 
(oscillometric) upper arm devices is preferred over auscultation (Grade C). (Unless 
specified otherwise, electronic [oscillometric] measurement should be used). 
3. In patients with large arm circumference when standard upper arm measurement methods 
cannot be used, validated wrist devices (utilized with the arm and wrist supported at heart 
level) may be used for BP estimation (Grade D; new guideline).   
4. Four approaches can be used to assess BP: 
i. AOBP is the preferred method of performing in-office BP measurement 
(Grade D). When using AOBP (see Supplemental Table S2, AOBP), a 
displayed mean SBP ≥135 mm Hg or DBP ≥85 mm Hg DBP is high 
(Grade D).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11
ii. When using non-AOBP, a mean systolic BP (SBP) ≥140 mm Hg or 
diastolic BP (DBP) ≥90 mm Hg is high, and an SBP between 130-139 mm 
Hg and/or a DBP between 85-89 mm Hg is high-normal (Grade C). 
iii. Using ambulatory BP monitoring (see Guidelines in Section IV, 
Ambulatory BP Monitoring), patients can be diagnosed as hypertensive if 
the mean awake SBP is ≥135 mm Hg or the DBP is ≥85 mm Hg or if the 
mean 24-hour SBP is ≥130 mm Hg or the DBP is ≥80 mm Hg (Grade C).  
iv. Using home BP monitoring (see Guidelines in Section III, Home BP 
Monitoring), patients can be diagnosed as hypertensive if the mean SBP is 
≥135 mm Hg or the DBP is ≥85 mm Hg (Grade C). If the office BP 
measurement is high and the mean home BP is <135/85 mm Hg, it is 
advisable to either repeat home monitoring to confirm the home BP is 
<135/85 mm Hg or perform 24-hour ambulatory BP monitoring to 
confirm that the mean 24-hour ambulatory BP monitoring is <130/80 mm 
Hg and the mean awake ambulatory BP monitoring is <135/85 mm Hg 
before diagnosing white coat hypertension (Grade D). 
 
II. Criteria for diagnosis of hypertension and guidelines for follow-up  
Background. A hypertension diagnostic algorithm for adults is shown in Figure 1. The new 
guidelines for 2018 address measurement methods for BP follow-up in adults with confirmed 
hypertension and in cases complicated by white coat effect.  
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Evidence-based recommendations for follow-up BP assessment are very important as they 
frequently inform BP treatment initiation and/or intensification.  However, there are patient, 
procedure, and device sources of measurement variation that can have significant clinical 
implications.41,42 Several studies have demonstrated that routine manual BP reading (SBP/DBP) 
are on average 9/6 mm Hg higher when compared with the corresponding research quality 
manual BP measurements.43,44 This can lead to significant misclassification of hypertensive 
status and inappropriate treatment.43,45  Thus, ensuring standardization and systematic 
measurement in the follow-up of adults with hypertension will help obtain accurate measurement 
and promote safe and appropriate BP treatment. 
 
Creating recommendations for specific follow-up measurement methods requires evidence 
(ideally from randomized controlled trials, RCTs) that evaluate different types of BP 
measurement methods and have a sufficient length of follow-up to allow comparisons of 
clinically important outcomes (morbidity and mortality) among the different measurement 
methods. Unfortunately, these data are not available.  To date, there is only one low-quality RCT 
of nearly 1,300 participants with primary hypertension which compared clinical outcomes for 
those whose antihypertensive treatment was guided by 24-hour ambulatory BP monitoring 
versus by usual office-based practice.46 While ambulatory BP monitoring-guided management 
was associated with a significant reduction in cardiovascular events and mortality after 4.7 years 
of follow-up, this trial had significant methodologic limitations (including differential exclusions 
after randomization and highly asymmetric loss to follow-up between trial arms).  Other trials of 
measurement strategies have been completed (8 RCTs with almost 1,900 participants) but are of 
shorter duration and evaluated surrogate outcomes.47-54 These studies compared out-of-office BP 
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measurement methods (ambulatory or home BP monitoring) with office-based BP measurements 
and had significant variation in study methodologies, approaches to out-of-office BP 
management, and BP treatment thresholds. Overall, the out-of-office measurement groups had 
lower treatment intensity and higher BP values, in keeping with white coat effect being identified 
and managed less intensively, while the short-term intermediate outcomes were similar to office-
based measurement approaches.  
 
In summary, there is limited evidence on measuring follow-up BPs in adults with hypertension, 
and thus, at present, there are insufficient data to make a recommendation for a single 
measurement method.  What has been established is that measurement variation is common and 
concerning, thus standardized methods of BP measurement should be employed, preferably 
using electronic (oscillometric) devices (Supplemental Table S2). 
 
For hypertensive patients with white coat effect, no trial has specifically examined optimal 
follow-up strategies to date. In RCTs of BP follow-up strategies, patients in whom 
antihypertensive medications have either been reduced or stopped are thought to represent those 
individuals with white coat effect.  Two RCTs comparing the use of home with office BP 
measurements demonstrated a significant reduction in antihypertensive medication use without 
changes in other clinical cardiovascular surrogate outcomes when home BP monitoring was 
used.47,53  Similarly, reduction in antihypertensive medications use was observed in another RCT 
when ambulatory BP monitoring was used to titrate medications.49  All three RCTs are limited, 
however, by the use of the same BP target in both arms regardless of measurement method.  
Overall, this limited evidence suggests that either ambulatory or home BP monitoring can be 
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used for BP follow-up in patients with white coat effect, though there remains a paucity of data 
on the specific frequency of monitoring to guide clinical practice. 
 
Guidelines. 
1. At initial presentation, patients demonstrating features of a hypertensive urgency or 
emergency (Supplemental Table S3) should be diagnosed as hypertensive and require 
immediate management (Grade D). In all other patients, at least 2 more readings should 
be taken during the same visit. If using AOBP, the BP calculated and displayed by the 
device should be used. If using non-AOBP measurement, the first reading should be 
discarded and the latter readings averaged. 
2. If the visit 1 office BP measurement is high-normal (thresholds outlined in Section I, 
Guideline 3) annual follow-up is recommended (Grade C).  
3. If the visit 1 mean AOBP or non-AOBP measurement is high (thresholds outlined in 
Section I, Guideline 3), a history and physical examination should be performed and, if 
clinically indicated, diagnostic tests to search for target organ damage (Supplemental 
Table S4) and associated cardiovascular risk factors (Supplemental Table S5) should be 
arranged within 2 visits. Exogenous factors that can induce or aggravate hypertension 
should be assessed and removed if possible (Supplemental Table S6). Visit 2 should be 
scheduled within 1 month (Grade D). 
4. If the visit 1 mean AOBP or non-AOBP SBP is ≥180 mm Hg and/or DBP is ≥110 mm 
Hg then hypertension is diagnosed (Grade D). 
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5. If the visit 1 mean AOBP SBP is 135-179 mm Hg and/or DBP is 85-109 mm Hg OR the 
mean non-AOBP SBP is 140-179 mm Hg and/or DBP is 90-109 mm Hg, out-of-office 
BP measurements should be performed before visit 2 (Grade C).  
i. Ambulatory BP monitoring is the recommended out-of-office 
measurement method (Grade D). Patients can be diagnosed with 
hypertension according to the thresholds outlined in Section I, Guideline 
3. 
ii. Home BP monitoring is recommended if ambulatory BP monitoring is not 
tolerated, not readily available, or because of patient preference (Grade 
D). Patients can be diagnosed with hypertension according to the 
thresholds outlined in Section I, Guideline 3.   
iii. If the out-of-office BP average is not elevated, white coat hypertension 
should be diagnosed and pharmacologic treatment should not be instituted 
(Grade C). 
6. If the out-of-office measurement, although preferred, is not performed after visit 1, then 
patients can be diagnosed as hypertensive using serial office BP measurement visits if 
any of the following conditions are met: 
i. At visit 2, mean non-AOBP measurement (averaged across all visits) is 
≥140 mm Hg SBP and/or ≥90 mm Hg DBP in patients with macrovascular 
target organ damage, diabetes mellitus, or chronic kidney disease 
(glomerular filtration rate <60 mL/min/1.73m2) (Grade D);  
ii. At visit 3, mean non-AOBP measurement (averaged across all visits) is 
≥160 mm Hg SBP or ≥100 mm Hg DBP;  
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iii. At visit 4 or 5, mean non-AOBP measurement (averaged across all visits) 
is ≥140 mm Hg SBP or ≥90 mm Hg DBP. 
7. Investigations for secondary causes of hypertension should be initiated in patients with 
suggestive clinical and/or laboratory features (outlined in Sections V, VII, and VIII) 
(Grade D).   
8. If at the last diagnostic visit the patient is not diagnosed as hypertensive and has no 
evidence of macrovascular target organ damage, the patient’s BP should be assessed at 
yearly intervals (Grade D).   
9. Hypertensive patients actively modifying their health behaviors should be followed-up at 
3- to 6-month intervals. Shorter intervals (every 1 or 2 months) are needed for patients 
with higher BPs (Grade D). 
10. Patients on antihypertensive drug treatment should be seen monthly or every 2 months, 
depending on the level of BP, until readings on 2 consecutive visits are below their target 
(Grade D). Shorter intervals between visits will be needed for symptomatic patients and 
those with severe hypertension, intolerance to antihypertensive drugs, or target organ 
damage (Grade D). When the target BP has been reached, patients should be seen at 3- to 
6-month intervals (Grade D).  
11. Standardized office BP measurement should be used for follow-up. Measurement using 
electronic (oscillometric) upper arm devices is preferred over auscultation (Grade C; new 
guideline). 
12. Ambulatory BP monitoring or home BP is recommended for follow-up of patients with 
demonstrated white coat effect (Grade D; new guideline).   
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III. Home BP measurement  
A suggested protocol for home BP monitoring is presented in Supplemental Table S2. 
 
Guidelines. 
1. Home BP monitoring can be used in the diagnosis of hypertension (Grade C).  
2. The use of home BP monitoring on a regular basis should be considered for patients with 
hypertension, particularly those with: 
i. Diabetes mellitus (Grade D);  
ii. Chronic kidney disease (Grade C); 
iii. Suspected non-adherence (Grade D); 
iv. Demonstrated white coat effect (Grade C); 
v. BP controlled in the office but not at home (masked hypertension) (Grade 
C). 
3. When white coat hypertension is suggested by home BP monitoring, its presence should 
be confirmed by repeat home BP monitoring (Guideline 7 in this section) or ambulatory 
BP monitoring before treatment decisions are made (Grade D). 
4. Patients should be advised to purchase and use only home BP monitoring devices that are 
appropriate for the individual and have met standards of the Association for the 
Advancement of Medical Instrumentation, the most recent requirements of the British 
Hypertension Society protocol, or the International Protocol for validation of automated 
BP measuring devices. Patients should be encouraged to use devices with data recording 
capabilities or automatic data transmission to increase the reliability of reported home BP 
monitoring (Grade D). 
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5. Home SBP values ≥135 mm Hg or DBP values ≥85 mm Hg should be considered to be 
elevated and associated with an increased overall mortality risk (Grade C). 
6. Health care professionals should ensure that patients who measure their BP at home have 
adequate training and, if necessary, repeat training in measuring their BP. Patients should 
be observed to determine that they measure BP correctly and should be given adequate 
information about interpreting these readings (Grade D). 
7. Home BP monitoring for assessing white coat hypertension or sustained hypertension 
should be based on duplicate measures, morning and evening, for an initial 7-day period. 
First-day home BP values should not be considered (Grade D).   
 
IV. Ambulatory BP measurement  
A suggested protocol for ambulatory BP monitoring is presented in Supplemental Table S2. 
 
 Guidelines. 
1. Ambulatory BP monitoring can be used in the diagnosis of hypertension (Grade C). 
Ambulatory BP monitoring should be considered when an office-induced increase in BP 
is suspected in treated patients with: 
i. BP that is not below target despite receiving appropriate chronic 
antihypertensive therapy (Grade C); 
ii. Symptoms suggestive of hypotension (Grade C); 
iii. Fluctuating office BP readings (Grade D). 
2. Ambulatory BP monitoring upper arm devices that have been validated independently 
using established protocols must be used (see www.dableducational.org) (Grade D).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 19
3. Therapy adjustment should be considered in patients with a mean 24-hour ambulatory BP 
monitoring SBP of ≥130 mm Hg and/or DBP of ≥80 mm Hg, or a mean awake SBP of 
≥135 mm Hg and/or DBP of ≥85 mm Hg (Grade D).  
4. The magnitude of changes in nocturnal BP should be taken into account in any decision 
to prescribe or withhold drug therapy based upon ambulatory BP monitoring (Grade C) 
because a decrease in nocturnal BP of <10% is associated with increased risk of 
cardiovascular events. 
 
V. Routine and optional laboratory tests for the investigation of patients with hypertension 
Guidelines. 
1. Routine laboratory tests that should be performed for the investigation of all patients with 
hypertension include the following: 
i. Urinalysis (Grade D);  
ii. Blood chemistry (potassium, sodium, and creatinine) (Grade D);  
iii. Fasting blood glucose and/or glycated hemoglobin (A1c) (Grade D); 
iv. Serum total cholesterol, low-density lipoprotein, high-density lipoprotein 
(HDL), non-HDL cholesterol, and triglycerides (Grade D); lipids may be 
drawn fasting or non-fasting (Grade C); and, 
v. Standard 12-lead electrocardiography (Grade C). 
2. Assess urinary albumin excretion in patients with diabetes (Grade D). 
3. All treated hypertensive patients should be monitored according to the current Diabetes 
Canada guidelines for the new appearance of diabetes (Grade B). 
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4. During the maintenance phase of hypertension management, tests (including those for 
electrolytes, creatinine, and fasting lipids) should be repeated with a frequency reflecting 
the clinical situation (Grade D). 
 
VI. Assessment of overall cardiovascular risk in hypertensive patients 
Background. Global cardiovascular risk assessment is often done through the use of risk 
calculators, including the Framingham risk score, www.myhealthcheckup.com and www.score-
canada.ca. Estimation and reporting of an individual’s global cardiovascular risk may help 
improve risk perception,55 facilitate informed discussions between physicians and patients 
regarding health behaviours,55-57 and potentially improve health outcomes,57,58 with little 
evidence of harm on psychological wellbeing.57  Counselling efforts aimed at improving health 
behaviours (such as promoting a healthful diet, weight management, and physical activity) 
appear effective in lowering BP. A recent meta-analysis of 88 RCTs reported that counseling 
interventions targeting both a healthful diet and increasing physical activity led to modest 
lowering of SBP (data from 22 RCTs of 57,953 participants; -1.26 mm Hg; 95% confidence 
interval [CI], -1.77 to -0.75) and DBP (data from 23 RCTs of 58,022 participants; -0.49 mm Hg; 
95% CI, -0.82 to -0.16) over 6 to 12 months in individuals at low cardiovascular risk.56  As such, 
global cardiovascular risk assessment can be considered as a tool to engage individuals in 
conversations to improve health behaviours to lower BP. 
 
Guidelines. 
1. Global cardiovascular risk should be assessed. Multifactorial risk assessment models can 
be used to:  
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a. Predict more accurately an individual’s global cardiovascular risk (Grade A); 
b. Help engage individuals in conversations about health behaviour change to lower 
BP (Grade D; new guideline); and, 
c. Use antihypertensive therapy more efficiently (Grade D).    
In the absence of Canadian data to determine the accuracy of risk calculations, avoid 
using absolute levels of risk to support treatment decisions (Grade C). 
2. Consider informing patients of their global risk to improve the effectiveness of risk factor 
modification (Grade B). Consider also using analogies that describe comparative risk 
such as "cardiovascular age," "vascular age," or "heart age" to inform patients of their 
risk status (Grade B).   
 
VII. Assessment for renovascular hypertension 
Guidelines. 
1. Patients presenting with ≥2 of the following clinical clues listed below, suggesting 
renovascular hypertension, should be investigated (Grade D): 
i. Sudden onset or worsening of hypertension and age >55 or <30 years; 
ii. Presence of an abdominal bruit; 
iii. Hypertension resistant to ≥3 drugs; 
iv. Increase in serum creatinine level ≥30% associated with use of an angiotensin 
converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB); 
v. Other atherosclerotic vascular disease, particularly in patients who smoke or 
have dyslipidemia;  
vi. Recurrent pulmonary edema associated with hypertensive surges.   
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 22
2. When available, the following tests are recommended to aid in the usual screening for 
renal vascular disease: captopril-enhanced radioisotope renal scan, Doppler sonography, 
magnetic resonance angiography, and computer tomography angiography (for those with 
normal renal function) (Grade B).  Captopril-enhanced radioisotope renal scan is not 
recommended for those with chronic kidney disease (glomerular filtration rate <60 
mL/min/1.73m2) (Grade D). 
3. Patients with hypertension and presenting with at least one of the following clinical clues 
should be investigated for fibromuscular dysplasia (FMD)-related renal artery stenosis 
(Grade D): 
i. Age <30 years, especially in non-obese women; 
ii. Hypertension resistant to ≥3 drugs;  
iii. Significant (>1.5cm), unexplained asymmetry in kidney sizes; 
iv. Abdominal bruit without apparent atherosclerosis; 
v. FMD in another vascular territory; 
vi. Positive family history for FMD. 
4. In patients with confirmed renal FMD (Grade D): 
i. Screening for cervicocephalic lesions and intracranial aneurysm is 
recommended; 
ii. Screening for FMD in other vascular beds in the presence of suggestive 
symptoms is recommended. 
5. The following tests are recommended to screen for renal FMD (both with similar 
sensitivity and specificity) (Grade D): magnetic resonance angiography and computed 
tomography angiography. 
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VIII. Assessment for endocrine hypertension 
A. Hyperaldosteronism: screening and diagnosis: 
Guidelines. 
1. Screening for hyperaldosteronism should be considered in hypertensive patients with the 
following (Grade D):  
i. Unexplained spontaneous hypokalemia (K+ <3.5 mmol/L) or marked diuretic-
induced hypokalemia (K+ <3.0 mmol/L); 
ii. Resistance to treatment with ≥3 drugs; 
iii. An incidental adrenal adenoma. 
2. Screening for hyperaldosteronism should include assessment of plasma aldosterone and 
plasma renin activity or plasma renin (Supplemental Table S7).   
3. For patients with suspected hyperaldosteronism (on the basis of the screening test, 
Supplemental Table S7, Item ii), a diagnosis of primary aldosteronism should be 
established by demonstrating inappropriate autonomous hypersecretion of aldosterone 
using at least one of the manoeuvres listed in Supplemental Table S7, Item iii. When the 
diagnosis is established, the abnormality should be localized using any of the tests 
described in Supplemental Table S7, Item iv.    
4. In patients with primary aldosteronism and a definite adrenal mass who are eligible for 
surgery, adrenal venous sampling is recommended to assess for lateralization of 
aldosterone hypersecretion. Adrenal vein sampling should be performed exclusively by 
experienced teams working in specialized centres (Grade C). 
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B. Pheochromocytoma and paraganglioma: screening and diagnosis 
Guidelines. 
1. If pheochromocytoma or paraganglioma is strongly suspected, the patient should be 
referred to a specialized hypertension center, particularly if biochemical screening tests 
(Supplemental Table S8) have already been found to be positive (Grade D). 
2. The following patients should be considered for screening for pheochromocytoma or 
paraganglioma (Grade D): 
i. Patients with paroxysmal, unexplained, labile, and/or severe (BP ≥180/ 
110 mm Hg) sustained hypertension refractory to usual antihypertensive 
therapy;  
ii. Patients with hypertension and multiple symptoms suggestive of 
catecholamine excess (e.g., headaches, palpitations, sweating, panic 
attacks, and pallor); 
iii. Patients with hypertension triggered by β-blockers, monoamine oxidase 
inhibitors, micturition, changes in abdominal pressure, surgery, or 
anesthesia; 
iv. Patients with an incidentally discovered adrenal mass; 
v. Patients with a predisposition to hereditary causes (e.g., multiple 
endocrine neoplasia 2A or 2B, von Recklinghausen neurofibromatosis 
type 1, or Von Hippel-Lindau disease);   
vi. For patients with positive biochemical screening tests, localization of 
pheochromocytomas or paragangliomas should employ magnetic 
resonance imaging (preferable), computed tomography (if magnetic 
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resonance imaging unavailable), and/or iodine I-131 meta-
iodobenzylguanidine (MIBG) scintigraphy (Grade C for each modality). 
 
IX. Role of echocardiography 
Guidelines. 
1. Routine echocardiographic evaluation of all hypertensive patients is not recommended 
(Grade D).  
2. An echocardiogram for assessment of left ventricular hypertrophy is useful in selected 
cases to help define the future risk of cardiovascular events (Grade C). 
3. Echocardiographic assessment of left ventricular mass, as well as of systolic and diastolic 
left ventricular function is recommended for hypertensive patients suspected to have left 
ventricular dysfunction or coronary artery disease (Grade D).  
4. Patients with hypertension and evidence of heart failure should have an objective 
assessment of left ventricular ejection fraction, either by echocardiogram or nuclear 
imaging (Grade D). 
 
Hypertension Canada’s 2018 Guidelines 
Prevention and Treatment of Hypertension in Adults 
 
Hereafter, all BP treatment thresholds and targets refer to non-AOBP measurements performed 
in office (see Supplemental Table S2, section on Recommended Technique for Automated Office 
Blood Pressure [AOBP]), because most of the supporting evidence is derived from studies using 
this BP measurement method. A summary of the potential factors that should be considered 
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when selecting specific drug therapy for individualized treatment is presented in Table 1. BP 
thresholds for initiation of treatment and BP treatment targets are summarized in Table 2 and 
Hypertension Canada’s definition of high-risk patients are presented in Table 3. 
 
I. Health behaviour management 
Guidelines. 
A. Physical exercise 
For non-hypertensive individuals (to reduce the possibility of becoming hypertensive) or 
for hypertensive patients (to reduce their BP), prescribe the accumulation of 30-60 
minutes of moderate intensity dynamic exercise (e.g., walking, jogging, cycling, or 
swimming) 4-7 days per week in addition to the routine activities of daily living (Grade 
D). Higher intensities of exercise are not more effective (Grade D). For non-hypertensive 
or stage 1 hypertensive individuals, the use of resistance or weight training exercise (such 
as free weight lifting, fixed weight lifting, or handgrip exercise) does not adversely 
influence BP (Grade D).  
B. Weight reduction  
1. Height, weight, and waist circumference should be measured and body mass index 
calculated for all adults (Grade D). 
2. Maintenance of a healthy body weight (body mass index 18.5 to 24.9 kg/m2, and waist 
circumference <102 cm for men and <88 cm for women) is recommended for non-
hypertensive individuals to prevent hypertension (Grade C) and for hypertensive patients 
to reduce BP (Grade B). All overweight hypertensive individuals should be advised to 
lose weight (Grade B).  
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3. Weight loss strategies should employ a multidisciplinary approach that includes dietary 
education, increased physical activity, and behavioural intervention (Grade B).  
C. Alcohol consumption 
To prevent hypertension and reduce BP in hypertensive adults, individuals should limit 
alcohol consumption to ≤ 2 drinks per day, and consumption should not exceed 14 
standard drinks per week for men and 9 standard drinks per week for women (Grade B). 
(Note: One standard drink is considered to be equivalent of 13.6 g or 17.2 mL of ethanol 
or approximately 44 mL [1.5 oz] of 80 proof [40%] spirits, 355 mL [12 oz] of 5% beer, 
or 148 mL [5 oz] of 12% wine.) 
D. Diet  
It is recommended that hypertensive patients and normotensive individuals at increased 
risk of developing hypertension consume a diet that emphasizes fruits, vegetables, low-
fat dairy products, whole grain foods rich in dietary fibre, and protein from plant sources 
that is reduced in saturated fat and cholesterol (Dietary Approaches to Stop Hypertension 
[DASH] diet;59-62 Supplemental Table S9) (Grade B).  
E. Sodium intake 
To prevent hypertension and reduce BP in hypertensive adults, consider reducing sodium 
intake towards 2000 mg (5 g of salt or 87 mmol of sodium) per day (Grade A).  
F. Calcium and magnesium intake 
Supplementation of calcium and magnesium is not recommended for the prevention or 
treatment of hypertension (Grade B).  
G. Potassium intake 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 28
In patients not at risk of hyperkalemia (see Table 4), increase dietary potassium intake to 
reduce BP (Grade A). 
H. Stress management 
In hypertensive patients in whom stress may be contributing to high BP, stress 
management should be considered as an intervention (Grade D). Individualized 
cognitive-behavioural interventions are more likely to be effective when relaxation 
techniques are used (Grade B). 
 
II. Indications for drug therapy for adults with hypertension without compelling 
indications for specific agents 
Guidelines. 
1. Antihypertensive therapy should be prescribed for average DBP measurements of ≥100 
mm Hg (Grade A) or average SBP measurements of ≥160 mm Hg (Grade A) in patients 
without macrovascular target organ damage or other cardiovascular risk factors. 
2. Antihypertensive therapy should be strongly considered for average DPB readings ≥90 
mm Hg (Grade A) or for average SBP readings ≥140 mm Hg (Grade B for 140-160 mm 
Hg; Grade A for >160 mm Hg) in the presence of macrovascular target organ damage or 
other independent cardiovascular risk factors.   
  
III. Choice of therapy for adults with hypertension without compelling indications for 
specific agents 
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A. Indications for drug therapy for adults with diastolic hypertension with or without 
systolic hypertension 
Guidelines. 
1. Initial therapy should be with either monotherapy or single pill combination (SPC).   
i. Recommended monotherapy choices are: 
a. a thiazide/thiazide-like diuretic (Grade A), with longer-acting 
diuretics preferred (Grade B),  
b. a β-blocker (in patients younger than 60 years; Grade B),  
c. an ACE inhibitor (in non-black patients; Grade B), 
d. an ARB (Grade B), or 
e. a long-acting calcium channel blocker (CCB) (Grade B). 
ii. Recommended SPC choices are those in which an ACE inhibitor is 
combined with a CCB (Grade A), ARB with a CCB (Grade B), or ACE 
inhibitor or ARB with a diuretic (Grade B). 
iii. Hypokalemia should be avoided in patients treated with thiazide/thiazide-
like diuretic monotherapy (Grade C).  
2. Additional antihypertensive drugs should be used if target BP levels are not achieved 
with standard-dose monotherapy (Grade B). Add-on drugs should be chosen from first-
line choices. Useful choices include a thiazide/thiazide-like diuretic or CCB with either: 
ACE inhibitor, ARB or β-blocker (Grade B for the combination of thiazide/thiazide-like 
diuretic and a dihydropyridine CCB; Grade A for the combination of dihydropyridine 
CCB and ACE inhibitor; and Grade D for all other combinations). Caution should be 
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exercised in combining a non-dihydropyridine CCB and a β-blocker (Grade D). The 
combination of an ACE inhibitor and an ARB is not recommended (Grade A).  
3. If BP is still not controlled with a combination of 2 or more first-line agents, or there are 
adverse effects, other antihypertensive drugs may be added (Grade D).   
4. Possible reasons for poor response to therapy (Supplemental Table S10) should be 
considered (Grade D).  
5. α-Blockers are not recommended as first-line agents for uncomplicated hypertension 
(Grade A); β-blockers are not recommended as first-line therapy for uncomplicated 
hypertension in patients 60 years of age or older (Grade A); and ACE inhibitors are not 
recommended as first-line therapy for uncomplicated hypertension in black patients 
(Grade A). However, these agents may be used in patients with certain comorbid 
conditions or in combination therapy. 
 
B. Indications for drug therapy for adults with isolated systolic hypertension 
Guidelines. 
1. Initial therapy should be single-agent therapy with a thiazide/thiazide-like diuretic (Grade 
A), a long-acting dihydropyridine CCB (Grade A), or an ARB (Grade B). If there are 
adverse effects, another drug from this group should be substituted. Hypokalemia should 
be avoided in patients treated with thiazide/thiazide-like diuretic monotherapy (Grade C).  
2. Additional antihypertensive drugs should be used if target BP levels are not achieved 
with standard-dose monotherapy (Grade B). Add-on drugs should be chosen from first-
line options (Grade D). 
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3. If BP is still not controlled with a combination of 2 or more first-line agents, or there are 
adverse effects, other classes of drugs (such as α-blockers, ACE inhibitors, centrally 
acting agents, or non-dihydropyridine CCBs) may be combined or substituted (Grade D). 
4. Possible reasons for poor response to therapy (Supplemental Table S10) should be 
considered (Grade D). 
5. α-Blockers are not recommended as first-line agents for uncomplicated isolated systolic 
hypertension (Grade A); and β-blockers are not recommended as first-line therapy for 
isolated systolic hypertension in patients aged 60 years or older (Grade A). However, 
both agents may be used in patients with certain comorbid conditions or in combination 
therapy. 
IV. Global vascular protection therapy for adults with hypertension without compelling 
indications for specific agents 
Guidelines. 
1. Statin therapy is recommended in hypertensive patients with 3 or more cardiovascular 
risk factors as defined in Supplemental Table S11 (Grade A in patients >40 years) or with 
established atherosclerotic disease (Grade A regardless of age). 
2. Consideration should be given to the addition of low dose acetylsalicylic acid (ASA) 
therapy in hypertensive patients ≥50 years of age (Grade B). Caution should be exercised 
if BP is not controlled (Grade C).  
3. Tobacco use status of all patients should be updated on a regular basis and health care 
providers should clearly advise patients to quit smoking (Grade C).   
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4. Advice in combination with pharmacotherapy (e.g., varenicline, bupropion, nicotine 
replacement therapy) should be offered to all smokers with a goal of smoking cessation 
(Grade C). 
5. For high-risk patients (Table 3), aged 50 years or older, with SBP levels ≥130 mm Hg, 
intensive management to target a SBP ≤120 mm Hg should be considered. Intensive 
management should be guided by AOBP measurements (see Diagnosis and Assessment 
Guidelines, Section I [Accurate measurement of BP], and Supplemental Table S2 
[Recommended Technique for Automated Office BP]). Patient selection for intensive 
management is recommended and caution should be taken in certain high-risk groups 
(Table 5; Grade B). 
 
V. Goals of therapy for adults with hypertension without compelling indications for specific 
agents 
Guidelines. 
1. The SBP treatment goal is a pressure level of <140 mm Hg (Grade C). The DBP treatment goal 
is a pressure level of <90 mm Hg (Grade A). 
 
VI. Treatment of hypertension in association with ischemic heart disease  
A. Guidelines for hypertensive patients with coronary artery disease (CAD) 
Guidelines. 
1. For most hypertensive patients with CAD, an ACE inhibitor or ARB is recommended 
(Grade A). 
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2. For hypertensive patients with CAD, but without coexisting systolic heart failure, the 
combination of an ACE inhibitor and ARB is not recommended (Grade B).  
3. For high-risk hypertensive patients, when combination therapy is being used, choices 
should be individualized. The combination of an ACE inhibitor and a dihydropyridine 
CCB is preferable to an ACE inhibitor and a thiazide/thiazide-like diuretic in selected 
patients (Grade A). 
4. For patients with stable angina pectoris but without prior heart failure, myocardial 
infarction, or coronary artery bypass surgery, either a β-blocker or CCB can be used as 
initial therapy (Grade B). 
5. Short-acting nifedipine should not be used (Grade D). 
6. When decreasing SBP to target levels in patients with established CAD (especially if 
isolated systolic hypertension is present), be cautious when the DBP is ≤60 mm Hg 
because of concerns that myocardial ischemia may be exacerbated, especially in patients 
with left ventricular hypertrophy (Grade D). 
 
B. Guidelines for patients with hypertension who have had a recent myocardial infarction  
Guidelines. 
1. Initial therapy should include both a β-blocker as well as an ACE inhibitor (Grade A).  
2. An ARB can be used if the patient is intolerant of an ACE inhibitor (Grade A in patients 
with left ventricular systolic dysfunction). 
3. CCBs may be used in patients after myocardial infarction when β-blockers are 
contraindicated or not effective. Nondihydropyridine CCBs should not be used when 
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there is heart failure, evidenced by pulmonary congestion on examination or radiography 
(Grade D).  
 
VII. Treatment of hypertension in association with heart failure 
Background.   The new 2018 guideline focuses on the use of a combined ARB-neprilysin-
inhibition (ARNI) in hypertensive patients with symptomatic heart failure with a reduced 
ejection fraction (HFrEF) and aligns closely with the Canadian Cardiovascular Society’s recent 
heart failure update.63  The Prospective Comparison of ARNI with ACEI to Determine Impact on 
Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF) RCT,64 included 8,442 
participants with symptomatic heart failure and a left ventricular ejection fraction of less than 
40% on standard evidence-based therapies.  Participants were randomized to receive either 
sacubitril-valsartan 200 mg bid (ARNI) or enalapril 10 mg bid. Treatment with sacubitril-
vasartan resulted in a reduction in the primary outcome (combination of cardiovascular death or 
hospitalization for heart failure) (hazard ratio [HR], 0.80; 95% CI, 0.73-0.87; p<0.001) as well as 
all-cause mortality (HR, 0.84; 95% CI 0.76-0.93; p<0.001) after a mean follow-up of 27 
months.64  Furthermore, ARNI was associated with a lower rate of progression of heart failure 
among surviving participants.65 The benefit of ARNI over enalapril was consistent in participants 
both with and without a history of hypertension, and in participants with baseline SBP both 
above and below the median value of 122 mm Hg.64  
Prior to use of an ARNI, as with all renin–angiotensin–aldosterone system inhibitor 
treatments, patient safety must be assessed.  Specifically, we recommend careful patient 
selection (Table 4) and monitoring patients for excessive hypotension, changes in renal function 
and potassium values (i.e., hyperkalemia).  At present, the combination of valsartan and 
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sacubitril is the only licensed ARNI product in Canada for the indication of heart failure and 
does not have a Health Canada indication for the treatment of hypertension.66  
   
Guidelines. 
1. In patients with systolic dysfunction (ejection fraction <40%), ACE inhibitors (Grade A) 
and β-blockers (Grade A) are recommended for initial therapy. Aldosterone antagonists 
(mineralocorticoid receptor antagonists) may be combined for patients with a recent 
cardiovascular hospitalization, acute myocardial infarction, elevated B-type natriuretic 
peptide or N-terminal pro-B-type natriuretic peptide level, or New York Heart 
Association Class II-IV symptoms (Grade A). Careful monitoring for hyperkalemia is 
recommended when combining an aldosterone antagonist to ACE inhibitor or ARB. 
Other diuretics are recommended as additional therapy if needed (Grade B for 
thiazide/thiazide-like diuretics for BP control, Grade D for loop diuretics for volume 
control). Beyond considerations of BP control, doses of ACE inhibitors or ARBs should 
be titrated to those found to be effective in trials unless adverse effects become manifest 
(Grade B).  
2. An ARB is recommended if ACE inhibitors are not tolerated (Grade A). 
3. A combination of hydralazine and isosorbide dinitrate is recommended if ACE inhibitors 
and ARBs are contraindicated or not tolerated (Grade B).  
4. For hypertensive patients whose BP is not controlled, an ARB may be combined with an 
ACE inhibitor and other antihypertensive drug treatment (Grade A). Careful monitoring 
should be used if combining an ACE inhibitor and an ARB because of potential adverse 
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effects such as hypotension, hyperkalemia, and worsening renal function (Grade C). 
Additional therapies may also include dihydropyridine CCBs (Grade C). 
5. An Angiotensin Receptor-Neprilysin Inhibitor combination should be used in place of an 
ACE inhibitor or ARB for patients with HFrEF (EF <40%) who remain symptomatic 
despite treatment with appropriate dose of guideline-directed HF therapy (usually a β-
blocker, an ACE-Inhibitor or ARB, and where appropriate, a mineralcorticoid antagonist) 
(Grade A; new guideline).  Eligible patients must have a serum potassium <5.2 mmol/L, 
an eGFR greater or equal to 30 mL/min/1.73m2 and close surveillance of serum 
potassium and creatinine (Grade A; new guideline). 
VIII. Treatment of hypertension in association with left ventricular hypertrophy 
Guidelines. 
1. Hypertensive patients with left ventricular hypertrophy should be treated with 
antihypertensive therapy to lower the rate of subsequent cardiovascular events (Grade C). 
2. The choice of initial therapy can be influenced by the presence of left ventricular 
hypertrophy (Grade D). Initial therapy can be drug treatment using ACE inhibitors, 
ARBs, long-acting CCBs or thiazide/thiazide-like diuretics. Direct arterial vasodilators 
such as hydralazine or minoxidil should not be used.  
 
IX. Treatment of hypertension in association with stroke 
Background. The revised guideline specifies target BP values prior to tissue plasminogen 
activator (tPA) therapy, i.e., alteplase, and for the subsequent 24 hours. It is well-established that 
patients with ischemic stroke who receive alteplase demonstrate better functional outcomes, as 
corroborated by a 2016 meta-analysis.67 Optimal BP management algorithms in the context of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 37
alteplase have not been specifically evaluated through definitive clinical trials, however there is 
an increased risk of intracerebral hemorrhage (ICH) with BP >185/110 and BP lowering at this 
threshold has been encouraged in adults that are candidates for thrombolysis.  This year, a target 
BP of <185/110 prior to alteplase administration and to target of <180/105 in the subsequent 24 
hours is recommended.  These treatment thresholds and targets have not been explicitly 
evaluated in the context of an RCT, however these thresholds and targets were used in the 
National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study which 
demonstrated the effectiveness of alteplase in acute stroke.68 It should be noted that not all 
alteplase stroke trials have used these BP levels during thrombolysis and have not demonstrated 
a significantly higher rate of ICH. However, given that ICH is a low frequency but concerning 
outcome, the Hypertension Canada Stroke Subgroup recommends using the NINDS protocol to 
ensure safe and optimal use of alteplase in the setting of acute stroke.  
 
Guidelines. 
A. BP management in acute ischemic stroke (onset to 72 hours) 
1. For patients with ischemic stroke not eligible for thrombolytic therapy, hypertension 
in the setting of acute ischemic stroke or transient ischemic attack should not be routinely 
treated (Grade D; revised wording). Extreme BP increases (e.g., SBP >220 mm Hg or 
DBP >120 mm Hg) may be treated to reduce the BP by approximately 15% (Grade D), 
and not more than 25%, over the first 24 hours with gradual reduction thereafter (Grade 
D). Avoid excessive lowering of BP because this might exacerbate existing ischemia or 
might induce ischemia, particularly in the setting of intracranial or extracranial arterial 
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occlusion (Grade D; revised wording). Pharmacological agents and routes of 
administration should be chosen to avoid precipitous decreases in BP (Grade D). 
2. For patients with ischemic stroke who are eligible for thrombolytic therapy, very high BP 
(>185/110 mm Hg) should be treated concurrently with thrombolysis to reduce the risk of 
hemorrhagic transformation (Grade B; revised guideline).  Blood pressure should be 
lowered to below 185/110 mm Hg prior to tPA therapy and to below 180/105 for the next 
24 hours (Grade D; revised guideline).  
B. BP management after acute ischemic stroke 
1. Strong consideration should be given to the initiation of antihypertensive therapy after the 
acute phase of a stroke or transient ischemic attack (Grade A). 
2. After the acute phase of a stroke, BP-lowering treatment is recommended to a target of 
consistently <140/90 mm Hg (Grade C). 
3. Treatment with an ACE inhibitor and thiazide/thiazide-like diuretic combination is 
preferred (Grade B). 
4. For patients with stroke, the combination of an ACE inhibitor and ARB is not 
recommended (Grade B). 
C. BP management in hemorrhagic stroke (onset to 72 hours) 
1. For patients with intracerebral hemorrhage in the hyperacute phase (in the first 24 hours) 
SBP lowering to <140 mm Hg should be avoided due to an absence of benefit (relative to 
a target of <180 mm Hg) (Grade A) and some suggestion of harm.   
 
X. Treatment of hypertension in association with non-diabetic chronic kidney disease 
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Guidelines. 
1. For patients with nondiabetic chronic kidney disease, target BP is <140/90 mm Hg 
(Grade B). 
2. For patients with hypertension and proteinuric chronic kidney disease (urinary protein 
>500 mg per 24 hours or albumin to creatinine ratio >30 mg/mmol), initial therapy 
should be an ACE inhibitor (Grade A) or an ARB if there is intolerance to ACE inhibitors 
(Grade B). 
3. Thiazide/thiazide-like diuretics are recommended as additive antihypertensive therapy 
(Grade D).  For patients with chronic kidney disease and volume overload, loop diuretics 
are an alternative (Grade D). 
4. In most cases, combination therapy with other antihypertensive agents might be needed 
to reach target BP levels (Grade D). 
5. The combination of an ACE inhibitor and ARB is not recommended for patients with 
nonproteinuric chronic kidney disease (Grade B). 
 
XI. Treatment of hypertension in association with renovascular disease 
Guidelines. 
1. Patients with hypertension attributable to atherosclerotic renal artery stenosis should be 
primarily medically managed because renal angioplasty and stenting offers no benefit 
over optimal medical therapy alone (Grade B).   
2. Renal artery angioplasty and stenting for atherosclerotic hemodynamically significant 
renal artery stenosis could be considered for patients with uncontrolled hypertension 
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resistant to maximally tolerated pharmacotherapy, progressive renal function loss, and 
acute pulmonary edema (Grade D). 
3. Patients with confirmed renal FMD should be referred to a hypertension specialist (Grade 
D). 
4. In patients with hypertension attributable to FMD-related renal artery stenosis, 
revascularization should be considered (Grade D). 
5. Renal artery angioplasty without stenting is recommended for treatment of FMD-related 
renal artery stenosis. Stenting is not recommended unless needed because of a peri-
procedural dissection. Surgical revascularization should be considered in case of complex 
lesions less amendable to angioplasty, stenosis associated with complex aneurysm, and 
restenosis despite two unsuccessful attempts of angioplasty (Grade D). 
  
XII. Treatment of hypertension in association with diabetes mellitus 
Guidelines. 
1. Persons with diabetes mellitus should be treated to attain SBP of <130 mm Hg (Grade C) 
and DBP of <80 mm Hg (Grade A) (these target BP levels are the same as the BP 
treatment thresholds) (revised wording).   
2. For persons with cardiovascular or kidney disease, including microalbuminuria, or with 
cardiovascular risk factors in addition to diabetes and hypertension, an ACE inhibitor or 
an ARB is recommended as initial therapy (Grade A).  
3. For persons with diabetes and hypertension not included in other guidelines in this 
section, appropriate choices include (in alphabetical order): ACE inhibitors (Grade A), 
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ARBs (Grade B), dihydropyridine CCBs (Grade A), and thiazide/thiazide-like diuretics 
(Grade A). 
4. If target BP levels are not achieved with standard-dose monotherapy, additional 
antihypertensive therapy should be used. For persons in whom combination therapy with 
an ACE inhibitor is being considered, a dihydropyridine CCB is preferable to a 
thiazide/thiazide-like diuretic (Grade A).   
 
XIII. Adherence strategies for patients 
Guidelines. 
1. Adherence to an antihypertensive prescription can be improved by a multipronged 
approach (Supplemental Table S12).  
 
XIV. Treatment of secondary hypertension due to endocrine causes 
Guidelines. 
1. Treatment of hyperaldosteronism and pheochromocytoma are outlined in Supplemental 
Tables S7 and S8, respectively.  
 
Hypertension Canada’s 2018 Guidelines.  Diagnosis and Assessment of Hypertension in 
Children 
Background. There are no changes to these guidelines35 for 2018. 
 
I.  Accurate measurement of BP in children 
Guidelines. 
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1. BP should be measured regularly in children 3 years of age and older by a health care 
professional using standardized pediatric techniques (Table 6) (Grade D).   
2. BP may be measured with a mercury sphygmomanometer, aneroid sphygmomanometer, 
or oscillometric device (Grade D).  Abnormal oscillometric values should be confirmed 
with auscultation (Grade C).  
3. BP varies with age, sex and height in children and, therefore, BP values should be 
compared to norms for age, sex, and height (Table 7) (Grade D). 
 
II. CRITERIA FOR DIAGNOSIS OF HYPERTENSION IN CHILDREN 
 
Guidelines. 
1. Using office BP measurements, children can be diagnosed as hypertensive if SBP or 
DBP is ≥95th percentile for age, sex, and height, measured on at least three separate 
occasions (Grade C).  
2. If the BP is ≥95th percentile, BP should be staged. Stage 1 is defined by BP between 
95th percentile and 99th percentile plus 5 mm Hg. Stage 2 is defined by BP >99th 
percentile plus 5 mm Hg (Grade D).  
i. If BP is Stage 1, BP measurements should be repeated on two more occasions 
within 1 month; if hypertension is confirmed, evaluation (as described in section 
IV – Routine Laboratory Tests for the Investigation of Children with 
Hypertension)35 and/or appropriate referral should be initiated within 1 month, or 
both (Grade D). 
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ii. If BP is Stage 2, prompt referral should be made for evaluation and therapy 
(Grade C). 
3. All children with suspected or confirmed hypertension should undergo a hypertension 
focused history and physical evaluation (Table 8) (Grade C). 
 
III.  ASSESSMENT OF OVERALL CARDIOVASCULAR RISK IN HYPERTENSIVE 
CHILDREN 
 
Guidelines. 
1. Cardiovascular risk factors should be assessed in hypertensive children (Grade C). 
 
IV.  ROUTINE LABORATORY TESTS FOR THE INVESTIGATION OF CHILDREN 
WITH HYPERTENSION 
 
Guidelines. 
1. Routine tests that should be performed for the investigation of all children with 
hypertension include:   
i. Blood chemistry (sodium, potassium, chloride, total CO2, and creatinine) (Grade 
D); 
ii. Urinalysis (Grade D);  
iii. Renal ultrasound (Grade D); 
2. Routine laboratory tests that should be performed for the assessment of cardiovascular 
risk in all children with hypertension include the following:  
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i. Fasting blood glucose (Grade C); 
ii. Serum total cholesterol and high-density lipoprotein cholesterol, low-density 
lipoprotein cholesterol, and triglycerides (Grade C). 
3. Routine tests that should be performed for the assessment of target organ damage in all 
children with hypertension include:  
i. Echocardiogram (Grade C); 
ii. Retinal examination (Grade C);   
iii. Albumin/creatinine ratio (first morning) (Grade D) 
 
V.  AMBULATORY BP MEASUREMENT IN CHILDREN 
 
Guidelines. 
1. For children with elevated office BP readings, ambulatory BP monitoring should be 
guided by a physician with expertise in pediatric hypertension; ambulatory BP 
monitoring is useful to classify BP (Table 9) (Grade C).   
2. Physicians should use only ambulatory BP monitoring devices that have been validated 
independently in children using established protocols. A standard approach to obtaining 
ambulatory BP monitoring readings should be used (Supplemental Table S13) (Grade 
D).   
3. Ambulatory BP monitoring levels should be interpreted with appropriate pediatric 
normative data for children 5 years of age or older or height of ≥120 cm (Grade D).   
 
VI.  ROLE OF ECHOCARDIOGRAPHY 
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Guidelines. 
2. Routine echocardiographic evaluation in children with confirmed hypertension is 
recommended (Grade D).   
3. The echocardiographic assessment should include measurements of left ventricular mass 
index, systolic and diastolic left ventricular function, and evaluation of the aortic arch 
(Grade D). 
 
Hypertension Canada’s 2018 Guidelines.  Prevention and Treatment of Hypertension in 
Children 
There are no changes to these guidelines36 for 2018. 
 
I. HEALTH BEHAVIOUR MANAGEMENT 
Guidelines. 
1. Height and weight should be measured and body mass index calculated for all children at 
routine health visits (Grade D). 
2. Achieving a healthy body weight (body mass index percentile <85%) is recommended 
for nonhypertensive individuals to prevent hypertension and for hypertensive children to 
reduce BP (Grade C). 
3. A comprehensive approach should include dietary education and increased physical 
activity (Grade C). 
 
II. INDICATIONS FOR DRUG THERAPY FOR CHILDREN WITH HYPERTENSION 
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Guidelines. 
1. Pharmacological therapy should be initiated when patients have: 
i. Symptomatic hypertension (Grade D); 
ii. Hypertensive target organ damage (Grade C); 
iii. Stage 2 hypertension (Grade D); 
iv. BP ≥90th percentile associated with diabetes mellitus type 1 or 2, chronic kidney 
disease or heart failure (Grade D); 
v. Stage 1 hypertension without target organ damage that persists (≥ 6 months) 
despite a trial of nonpharmacologic therapy (Grade D). 
2. In children with proven secondary hypertension, specific treatment of the underlying 
disease must be initiated by an expert in pediatric hypertension (Grade D).  
 
II. CHOICE OF DRUG THERAPY FOR CHILDREN WITH HYPERTENSION 
A. Recommendations for individuals with systolic and/or diastolic hypertension 
 
Guidelines. 
1. Initial therapy should be monotherapy.   
i. Recommended monotherapy choices are: 
a. An ACE inhibitor (Grade C);  
b. An ARB (Grade C); or 
c. A long-acting dihydropyridine CCB (Grade D).   
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ii. An alternate option is a β-blocker (Grade D) although they are less preferable due 
to the side effect profile in children.   
iii. If there are adverse effects, another drug from this group should be substituted. 
2. If BP goals are not achieved with standard-dose monotherapy for ≥6 months, children 
should be referred to an expert in pediatric hypertension (Grade D). 
3. ACE inhibitors (Grade C) and ARBs (Grade D) are not recommended as first-line agents 
in black patients and β-blockers are not recommended as first-line agents in children with 
asthma, diabetes (type 1 or type 2) and high-performance athletes (Grade D).  
 
IV.  GOALS OF THERAPY FOR CHILDREN WITH HYPERTENSION 
  
Guidelines. 
1. The treatment goal is office BP (systolic and diastolic) <95th percentile (Grade D). The 
goal for ambulatory BP monitoring is BP (systolic and diastolic) <95th percentile (Grade 
D).  
2. For patients with risk factors or target organ damage the goal is BP (systolic and 
diastolic) <90th percentile (Grade D).  
 
Summary/Future Directions 
These guidelines are a summary of the best available evidence to guide clinicians in the 
measurement, diagnosis, and treatment of hypertension in adults and children (key similarities 
and differences are summarized in Table 10). The next update for Hypertension Canada’s 
Guideline is planned for 2020 to allow for optimal dissemination of the 2018 Guidelines though 
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literature searches will be continued on an annual basis.  New evidence identified as being 
“practice changing” for clinicians (i.e., associated with a strong reduction in cardiovascular 
events or mortality; or a substantial reduction in resource utilization) will be brought forward for 
an interim update to ensure timely implementation of important evidence.  Priorities identified 
for the development of new guidelines in 2020 include, among others, the management of 
resistant hypertension (i.e., uncontrolled BP despite the use of ≥3 antihypertensive agents of 
different classes including a diuretic, or controlled BP with ≥4 agents),69-72 as well as updates on 
BP measurement methods and follow-up, and diagnosis of masked hypertension. 
 
Implementation 
Implementation and dissemination of the guidelines is a priority for Hypertension 
Canada. Many strategies are employed to reach a variety of providers who care for patients with 
hypertension. Efforts include knowledge exchange forums, targeted educational materials for 
primary care providers and patients, “Train the Trainer” teaching sessions, as well as slide kits 
and summary documents which are freely available online in French and English 
(www.hypertension.ca). Hypertension Canada receives feedback from end-users to continually 
improve guideline processes and content. The Research and Evaluation Committee conducts 
hypertension surveillance studies and reviews existing Canadian health surveys to identify gaps 
between current and best practices. 
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Table 1. Considerations in the individualization of pharmacological therapy in adults 
 
 Initial therapy Second-line therapy Notes and/or cautions 
 
 
Hypertension without other compelling indications 
Diastolic 
hypertension with or 
without systolic 
hypertension 
Monotherapy or SPC. Recommended 
monotherapy choices include 
thiazide/thiazide-like diuretics (with 
longer-acting diuretics preferred), β 
blockers, ACE inhibitors, ARBs, or 
long-acting CCB. Recommended SPC 
choices include combinations of an 
ACE inhibitor with CCB, ARB with 
CCB, or ACE inhibitor/ARB with a 
diuretic. (Consider ASA and statins in 
selected patients.) 
Further addition of first-line drugs Not recommended for monotherapy: α 
blockers, β blockers in those ≥60 years 
of age, ACE inhibitors in black 
people.  Hypokalemia should be 
avoided in those prescribed diuretics. 
ACE inhibitors, ARBs and direct renin 
inhibitors are potential teratogens, and 
caution is required if prescribing to 
women with child-bearing potential. 
Combination of an ACE-inhibitor with 
an ARB is not recommended.   
    
Isolated systolic 
hypertension 
without other 
compelling 
indications  
Thiazide/thiazide-like diuretics, ARBs 
or long-acting dihydropyridine CCBs 
Combinations of first-line drugs Same as diastolic hypertension with or 
without systolic hypertension. 
 
   
 
 
   
 
   
Diabetes mellitus  
Diabetes mellitus 
with 
microalbuminuria*, 
renal disease, 
cardiovascular 
ACE inhibitors or ARBs Addition of a dihydropyridine 
CCB is preferred over a 
thiazide/thiazide-like diuretic. 
A loop diuretic could be considered in 
hypertensive chronic kidney disease 
patients with extracellular fluid 
volume overload. 
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disease or additional 
cardiovascular risk 
factors  
    
Diabetes mellitus not 
included in the 
above category 
ACE inhibitors, ARBs, 
dihydropyridine CCBs or 
Thiazide/thiazide-like diuretics 
Combination of first-line drugs. If 
combination with ACE inhibitor 
is being considered, a 
dihydropyridine CCB is 
preferable to a thiazide/thiazide-
like diuretic. 
Normal urine microalbumin to 
creatinine ratio <2.0 mg/mmol  
    
Cardiovascular disease  
Coronary artery 
disease 
ACE inhibitors or ARBs; β blockers 
or CCBs for patients with stable 
angina 
When combination therapy is 
being used for high risk patients, 
an ACE inhibitor/dihydropyridine 
CCB is preferred. 
Avoid short-acting nifedipine. 
Combination of an ACE-inhibitor with 
an ARB is specifically not 
recommended.  Exercise caution when 
lowering SBP to target if DBP is ≤60 
mm Hg, especially in patients with 
LVH. 
 
   
Recent myocardial 
infarction 
β blockers and ACE inhibitors   
(ARBs if ACE inhibitor intolerant) 
Long-acting CCBs if β blocker  
contraindicated or not effective. 
Non-dihydropyridine CCBs should not 
be used with concomitant heart failure. 
 
   
Heart failure ACE inhibitors (ARBs if ACE 
inhibitor-intolerant) and β blockers.   
Aldosterone antagonists 
(mineralocorticoid receptor 
antagonists) may be added for patients 
with a recent cardiovascular 
hospitalization, acute myocardial 
infarction, elevated BNP or NT-
proBNP level, or NYHA Class II to IV 
symptoms. 
ACE inhibitor and ARB 
combined. Hydralazine/isosorbide 
dinitrate combination if ACE 
inhibitor and ARB contraindicated 
or not tolerated.  
Thiazide/thiazide-like or loop 
diuretics are recommended as 
additive therapy. Dihydropyridine 
CCB can also be used. 
A combined ARB/neprilysin-
Titrate doses of ACE inhibitors and 
ARBs to those used in clinical trials. 
Carefully monitor potassium and renal 
function if combining any of ACE 
inhibitor, ARB and/or aldosterone 
antagonist.  
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inhibitor is recommended (in 
place of an ACE inhibitor or 
ARB) in symptomatic patients 
with hypertension and HFrEF on 
standard guideline-based 
therapies. 
 
   
Left ventricular 
hypertrophy 
ACE inhibitor, ARB, long acting CCB 
or thiazide/thiazide-like diuretics. 
Combination of additional agents Hydralazine and minoxidil should not 
be used. 
 
   
Past stroke or TIA ACE inhibitor and a thiazide/thiazide-
like diuretic combination. 
Combination of additional agents Treatment of hypertension should not 
be routinely undertaken in acute stroke 
unless extreme BP elevation.  
Combination of an ACE inhibitor with 
an ARB is not recommended.   
Non-diabetic chronic kidney disease  
Non-diabetic chronic 
kidney disease with 
proteinuria† 
ACE inhibitors (ARBs if ACE 
inhibitor-intolerant) if there is 
proteinuria. 
Diuretics as additive therapy. 
Combinations of additional agents Carefully monitor renal function and 
potassium for those on an ACE 
inhibitor or ARB. Combinations of an 
ACE-inhibitor and ARB are not 
recommended in patients without 
proteinuria.  
    
Renovascular 
disease 
Does not affect initial treatment 
recommendations. 
Atherosclerotic renal artery stenosis 
should be primarily managed 
medically, while revascularization 
should be considered for renal 
fibromuscular dysplasia.  
Combinations of additional agents Caution with ACE inhibitors or ARB 
if bilateral renal artery stenosis or 
unilateral disease with solitary kidney. 
Renal artery angioplasty and stenting 
could be considered for patients with 
renal artery stenosis and complicated, 
uncontrolled hypertension. 
Other conditions  
Peripheral arterial 
disease 
Does not affect initial treatment 
recommendations. 
Combinations of additional agents Avoid β blockers with severe disease. 
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Dyslipidemia Does not affect initial treatment 
recommendations. 
Combinations of additional agents – 
 
   
Overall vascular 
protection 
Statin therapy for patients with 3 or 
more cardiovascular risk factors or 
atherosclerotic disease. 
Low dose ASA in patients ≥50 years 
Advise on smoking cessation and use 
pharmacotherapy for smoking 
cessation if indicated.  
– Caution should be exercised with the 
ASA recommendation if BP is not 
controlled. 
*Microalbuminuria is defined as persistent albumin to creatinine ratio >2.0 mg/mmol.  
†Proteinuria is defined as urinary protein >500 mg/24hr or albumin to creatinine ratio [ACR] >30 mg/mmol in two of three specimens.  
BP blood pressure; ACE Angiotensin converting enzyme; ARB Angiotensin receptor blocker; ASA Acetylsalicylic acid; CCB 
Calcium channel blocker; HFrEF Heart failure with reduced ejection fraction < 40%; NYHA New York Heart Association; TIA 
Transient ischemic attack; LVH Left ventricular hypertrophy; SPC Single pill combination. 
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Table 2.  Blood pressure thresholds for initiation of antihypertensive and treatment targets 
in adults 
 
 
Patient Population BP threshold (mm Hg) for 
initiation of antihypertensive 
therapy  
BP target (mm Hg) for 
treatment 
Low-risk (No target organ 
damage or cardiovascular risk 
factors)  
SBP ≥ 160 (Grade A) 
DBP ≥ 100 (Grade A) 
SBP < 140 (Grade A) 
DBP < 90 (Grade A) 
High-risk* of cardiovascular 
disease 
SBP ≥ 130 (Grade B) SBP < 120 (Grade B) 
Diabetes mellitus SBP ≥ 130 (Grade C) 
DBP ≥   80 (Grade A) 
SBP < 130 (Grade C) 
DBP < 80 (Grade A) 
All others SBP ≥ 140 (Grade C) 
DBP ≥  90 (Grade A) 
SBP < 140 (Grade A) 
DBP < 90 (Grade A) 
  
*see table 3; based upon automated office blood pressure measurement 
BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure 
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Table 3. Clinical indications defining high risk adult patients as candidates for intensive 
management 
 
Clinical or sub-clinical cardiovascular disease 
       OR 
Chronic kidney disease (non-diabetic nephropathy, proteinuria <1 g/d, *estimated glomerular 
filtration rate 20-59 mL/min/1.73m2) 
       OR 
†Estimated 10-year global cardiovascular risk ≥15%  
       OR 
Age ≥ 75 years  
Patients with one or more clinical indications should consent to intensive management. 
*Four variable Modification of Diet in Renal Disease (MDRD) equation 
†Framingham Risk Score73 
g/d, grams per day 
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Table 4. Risk factors for hyperkalemia 
 
Prior to advising an increase in potassium intake, the following types of patients, who are at high 
risk of developing hyperkalemia, should be assessed for suitability, and monitored closely: 
• Patients taking renin-angiotensin-aldosterone inhibitors 
• Patients on other drugs that can cause hyperkalemia (e.g., trimethoprim and sulfamethoxazole, 
amiloride, triamterene) 
• Chronic kidney disease (glomerular filtration rate <45 mL/min/1.73m2) 
• Baseline serum potassium >4.5 mmol/L 
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Table 5. Generalizability of intensive blood pressure lowering in adults: cautions and 
contraindications 
 
Limited or No Evidence  
Heart failure (left ventricular ejection fraction <35%) or recent myocardial infarction (within last 
3 months) 
Indication for, but not currently receiving, a β-blocker  
Institutionalized elderly  
Inconclusive evidence 
Diabetes Mellitus 
Prior stroke 
eGFR < 20 ml/min/1.73 m2 
Contraindications 
Patient unwilling or unable to adhere to multiple medications 
Standing SBP <110 mm Hg 
Inability to measure SBP accurately 
Known secondary cause(s) of hypertension 
 
eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure 
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Table 6. Standard approach for BP measurement in children (Grade D) 
1.     Children who will undergo BP measurement should avoid stimulant medications 
prior to evaluation. At the time of evaluation, the child should be seated in a quiet room 
for 5 minutes with back supported prior to the measurement of blood pressure. 
2.     The right arm is the preferred location for BP measurement for comparison to 
normative data due to the possibility of coarctation of the aorta, which may result in an 
erroneously low BP measurement being obtained in the left arm. 
3.      A cuff size with a bladder width that is at least 40% of the arm circumference and 
the cuff bladder length should cover 80-100% of the circumference of the arm. The arm 
should be bare and supported with the BP cuff at heart level. In order to obtain accurate 
measurements in children a range of pediatric and adult cuff sizes should be available. 
4.     The pressure should be increased rapidly to 30 mmHg above the level at which the 
radial pulse is extinguished.  
5.     The stethoscope should be placed below the bottom edge of the cuff and above the 
antecubital fossa. The bell or diaphragm of the stethoscope should be held gently and 
steadily over the brachial artery. 
6.     The control valve should be opened so that the rate of deflation of the cuff is 
approximately 2 mmHg per heartbeat.  
7.     The systolic level - the first appearance of a clear tapping sound (phase I 
Korotkoff) - and the diastolic level (*the point at which the sounds disappear (phase V 
Korotkoff)) should be recorded. In some children, Korotkoff sounds can be heard to 0 
mmHg. If Korotkoff sounds persist as the level approaches 0 mmHg, then the point of 
muffling of the sound is used (phase IV Korotkoff) to indicate the diastolic pressure.   
8.   The BP should be recorded to the closest 2 mm Hg on the manometer (or 1 mm Hg 
on electronic devices). 
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 Table 7. Determining normative data for BP values in children (Grade D) 
 
1.   The BP Tables utilize growth parameters as defined by the Centers for Disease 
Control and Prevention (CDC) growth charts. 
2.   The normative BP data obtained with auscultatory method includes the US 
National Health and Nutrition Examination Survey from 1999-2000. Normative BP 
data for oscillometric measurements are now available.  
3.   To determine BP percentile, use the standard CDC height charts to determine the 
height percentile. 
4.   Measure the child’s blood pressure.  Use the appropriate gender table. Locate the 
child’s age on the left side of the table and follow the age row horizontally across the 
table to the intersection of the line for the height percentile as shown in the vertical 
column. 
5.   The 50th, 90th, 95th, and 99th percentiles are defined for systolic and diastolic 
blood pressure based on gender, age and height. 
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 Table 8. History and physical examination of children (Grade C) 
 
1. Medical History:  
Symptoms 
▫ Of hypertension 
▫ Of an underlying disorder* 
 
Past Medical History 
▫ For underlying cause of hypertension*, including neonatal history 
 
Identify other cardiovascular risk factors including inactivity, smoking, and 
dietary factors 
Family History 
2. Patient physical examination: 
Height, weight, and body mass index 
Vital signs including upper and lower limb blood pressures 
Evaluation for signs of end-organ damage 
Fundi, cardiovascular and neurologic systems 
Evaluation for underlying cause of hypertension* 
*Systems to review include renal, cardiovascular, endocrine, and neurologic, as well as 
medications/drugs and sleep disorders 
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Table 9. Suggested schema to classify blood pressure in children  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BP, blood pressure; DBP, diastolic BP; SBP, systolic BP. 
 
Classification Office BP Mean ambulatory 
SBP or DBP  
during wake or 
sleep period, or 
both 
SBP or DBP load 
(%) 
White coat 
hypertension 
≥ 95th 
percentile 
< 95th percentile < 25 
Masked hypertension 
 
< 95th 
percentile 
≥ 95th percentile ≥ 25 
Ambulatory 
hypertension 
≥ 95th 
percentile 
≥ 95th percentile 25-50 
Severe ambulatory 
hypertension 
≥ 95th 
percentile 
≥ 95th percentile > 50 
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 Table 10.  Comparison of Hypertension Canada’s 2018 pediatric and adult guidelines for 
blood pressure measurement, hypertension diagnosis, assessment, and treatment 
 
ABPM: ambulatory blood pressure monitoring, ACE: angiotensin converting enzyme, ARB: angiotensin receptor 
blocker, BP: blood pressure, CCB: calcium channel blocker 
* For adults with diastolic with or without systolic hypertension, without compelling indications for specific agents 
  
 Pediatric Guidelines Adult Guidelines 
Measurement - Use standardized pediatric techniques and 
validated equipment (Table 6) 
- Oscillometric device or auscultation 
method for initial measurement 
- Elevated oscillometric values should be 
confirmed with auscultation 
- BP values should be compared to norms 
based on age, sex, and height (Table 7) 
- ABPM should be guided by experts in 
pediatric hypertension 
- Use standardized measurement techniques 
and validated equipment 
- Oscillometric devices are preferred over 
auscultation. Automated office blood pressure 
is the preferred method of performing in-
office BP measurement. 
- Elevated office BP measurements should be 
confirmed with out-of-office BP 
measurements including ABPM (preferable) 
or home BP monitoring where available  
Diagnosis - Diagnose by BP percentile based on norms 
for age, sex, and height and: 
- level of BP elevation 
- number of visits/ measurements 
- See Diagnosis and Assessment Section II 
- Diagnose by absolute BP value according to: 
- level of BP elevation 
- number of visits/ measurements 
- method of BP measurement 
- See Figure 1 
Assessment - History and physical examination 
- Cardiovascular risk factor assessment 
- Routine investigations for: 
- secondary causes of hypertension 
- cardiovascular risk factors 
- target organ damage 
- History and physical examination 
- Cardiovascular risk factor assessment 
- Routine investigations for: 
- secondary causes of hypertension 
- cardiovascular risk factors 
- target organ damage 
Management - Dietary education and increased physical 
activity 
- Initial pharmacologic therapy for primary 
hypertension is monotherapy with choice 
of ACE inhibitor, ARB, or CCB 
- If BP is not controlled with monotherapy, 
refer to an expert in pediatric hypertension 
- Dietary education, increased physical activity, 
alcohol limitation and stress management 
- *Initial pharmacologic therapy with either 
thiazide/thiazide-like diuretic, β-blocker, 
ACE inhibitor, ARB, or CCB monotherapy or 
single pill combination with ACE inhibitor + 
CCB, ARB + CCB, or ACE inhibitor/ARB + 
diuretic 
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FIGURE LEGEND 
 
Figure 1. Hypertension diagnostic algorithm for adults 
 
**************************** 
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